Back to news

November 30, 2018 | International,

Reinventing Drug Discovery and Development for Military Needs

Flying at 50,000 feet, diving deep in the ocean, or hiking for miles with gear through extreme climates, military service members face conditions that place unique burdens on their individual physiology. The potential exists to develop pharmacological interventions to help service members complete their toughest missions more safely and efficiently, and then recover more quickly and without adverse effects, but those interventions must work on complex physiological systems in the human body. They will not be realized under the prevailing system of drug discovery and development with its focus on engaging single molecular targets. DARPA created the Panacea program to pursue the means of rapidly discovering, designing, and validating new, multi-target drugs that work with the body's complexity to better support the physiological resilience and recovery of military service members.

The premise of Panacea is that the physiological systems of the human body work in complex and highly integrated ways. Drugs exert effects on our bodies by physically interacting with and changing the functional state of biomolecules that govern the functions of cells and tissues. Most drugs target proteins, which are the principle cellular workhorses. Ideally, drugs would target multiple proteins simultaneously to exert precise, network-level effects.

One major problem facing the drug development community is that the functional proteome — the complete collection of proteins and their roles in signaling networks — is largely dark to science. Despite being able to identify many of the proteins within a cell, researchers do not have a firm grasp on everything those proteins do and how they interact to affect physiology.

Due to this sparsity of structural and functional knowledge, the state of the art in drug development — what Panacea seeks to transform — is to engage only a very small fraction of known protein targets to achieve an effect. In fact, today's approach to drug design singles out individual proteins in certain cells. That hyper-specificity is an attempt to minimize the risk of side effects and speed time to market, but it also yields a thin stream of drugs, many of which have similar mechanisms and relatively muted effectiveness compared to what might be achieved using a multi-target, systems-based approach.

“The current roster of drugs approved by the U.S. Food and Drug Administration only targets about 549 proteins, yet the body can produce more than six million different protein variants,” said Tristan McClure-Begley, the Panacea program manager. “The opportunity space for pharmacological intervention is vast and effectively untapped, but to access it we need new technology for understanding and targeting the human functional proteome.”

Panacea will address the lack of functional knowledge about the proteome. DARPA's call to the research community is to consider complex physiological conditions relevant to military service members — for instance, metabolic stress during extreme endurance missions or pain and inflammation after injury; investigate the molecular mechanisms underlying those conditions; identify multiple, key molecular targets involved; and develop novel medicinal chemistry approaches to synthesize interventions that modulate those targets. DARPA believes that multi-target drugs will deliver safer and more efficacious solutions to military requirements for readiness and recovery over state-of-the-art interventions.

“Many of the most successful drugs produced in the past were found rather than made, and we knew what they did long before we knew how they did it,” McClure-Begley said. “To deliver improved interventions, we need to get to a place where we can investigate all of the potential proteins at play for a given condition and then prioritize sets of protein targets and signaling networks to effectively modulate physiological systems, regardless of what prior knowledge exists about those targets.”

The Panacea program aims to generate initial proof of concept for this new direction in drug discovery and development. Research will primarily involve animal models, human cell derived organoids, and high-throughput cell culture models. However, to support eventual transition to humans, DARPA will work with federal agencies to develop a regulatory pathway for future medical use. By the end of the five-year program, DARPA will require teams to submit novel drug candidates to the U.S. Food and Drug Administration for review as an Investigational New Drug or for Compassionate Use.

DARPA will hold a Proposers Day on December 14, 2018, in Arlington, Virginia, to provide more information about Panacea and answer questions from potential proposers. For details of the event, including registration requirements, visit https://go.usa.gov/xP6hD.

A forthcoming Broad Agency Announcement will fully describe the program structure and objectives.

https://www.darpa.mil/news-events/2018-11-28

On the same subject

  • Northrop Grumman to continue supporting legacy missile warning satellites

    June 30, 2020 | International, Aerospace

    Northrop Grumman to continue supporting legacy missile warning satellites

    Nathan Strout The Space and Missile Systems Center has issued a $222.5 million contract to continue supporting the Defense Program Support constellation, a legacy system that helps detect ballistic missile launches, nuclear detonations and space launches. Since the first payload was launched in 1970, DSP satellites have contributed to America's missile warning architecture by using infrared sensors in geosynchronous orbit to detect ballistic missile launches all around the world. The final DSP payload was launched in 2007. Northrop Grumman was the prime contractor for all DSP satellites. While the constellation has been superseded by the Space Based Infrared System (SBIRS), DSP satellites continue to operate on orbit. According to Northrop Grumman's website, the satellites have exceeded their design lives by 125 percent. And this new $222.5 million contract will help extend the constellation's lifetime even further. Under the decade-long contract, Northrop Grumman will provide “on-orbit satellite and anomaly resolution support, root cause analysis, mission threat analysis, mission test bed and space awareness and global exploitation,” which will help extend the lifetime of the constellation. Work is expected to be completed March 31, 2030. https://www.c4isrnet.com/battlefield-tech/space/2020/06/29/northrop-grumman-to-continue-supporting-legacy-missile-warning-satellites/

  • ‘We are not dupes’: France takes step away from US with fighter program

    September 10, 2018 | International, Aerospace

    ‘We are not dupes’: France takes step away from US with fighter program

    By: Pierre Tran PARIS — France has linked its search for independence from U.S. export rules with the Franco-German project for a future fighter jet, in a bid to boost foreign sales of the aircraft, the French armed forces minister said. France's effort to become less dependent on U.S. components and promote exports were written into the same letter of intent signed in June with Germany for the FCAS project, Florence Parly told AJPAE, the aeronautics and space journalists association, on Sept. 6. “The exportability of the (Future Combat Air System) is a key element to ensure the economic viability of the program,” she said. “We have to think as upstream as possible to secure this exportability.” The minister previously told parliamentarians the French government aims to cut its reliance on U.S. components in the wake of an American refusal to authorize the sale of parts for a French Scalp cruise missile requested by Egypt. French attempts to persuade Washington to lift restrictions under U.S. International Traffic in Arms Regulations have failed. Parly declined to give examples, but she said the problems Paris has encountered in the pursuit of foreign arms sales “stemmed in appearance from strategic factors and in reality from commercial competition." “We are not dupes,” she said. France needs to gradually cut its reliance on certain American components, although it is impossible to be completely independent, she admitted, adding that there is a plan to reduce that dependence. “Experience has led us to undertake this action,” she said. Companies should take the responsibility for greater independence, as they faced the consequences of failed export efforts, she said. “They are in the front line,” she said, noting that the government is in dialog with industry and that some companies already understand the situation and are fully committed. https://www.defensenews.com/air/2018/09/07/we-are-not-dupes-france-takes-step-away-from-us-with-fighter-program

  • Exclusive: Trump administration advances $2.9 billion drone sale to UAE - sources

    November 6, 2020 | International, Aerospace

    Exclusive: Trump administration advances $2.9 billion drone sale to UAE - sources

    By Mike Stone, Patricia Zengerle WASHINGTON (Reuters) - The U.S. State Department gave Congress notification it plans to sell 18 sophisticated armed MQ-9B aerial drones to the United Arab Emirates in a deal worth as much as $2.9 billion, people briefed on the notification said. The move comes on the heels of last week's notification of a potential sale of F-35 fighter jets to the middle-eastern country. This would mark the first armed drone export since the Trump administration reinterpreted a Cold War-era arms agreement between 34 nations to allow U.S. defense contractors to sell more drones to allies. Reuters has reported that UAE has long shown interest in purchasing drones from the United States and would be among the first customers in line after U.S. export policy changed this summer. A $600 million deal to sell four unarmed but weapons-ready MQ-9B SeaGuardian drones to Taiwan was the first to be formally notified to Congress on Tuesday. This informal notification for the Reaper-style drones is the precursor to the State Department's formal and public notification. The U.S. Senate Foreign Relations and House of Representatives Foreign Affairs committees - whose members have criticized UAE's role in civilian deaths in Yemen's civil war - have the ability to review and block weapons sales under an informal review process before the State Department sends its formal notification to the legislative branch. The U.S. State Department may wait to formally notify Congress of the sale once staff and members are briefed on the potential sale, one of the people said. The formal notification gives Congress 30 days to object to any sales. A U.S. State Department spokesman told Reuters, “As a matter of policy, the United States does not confirm or comment on proposed defense sales or transfers until they are formally notified to Congress.” The armed MQ-9B drones will also be equipped with maritime radar and could be delivered in 2024. The package notified to Congress is for 15 with an option for three additional drones, one of the people said. The UAE is also seeking a package of Boeing Co EA-18G Growlers, an electronic warfare version of the two-seat F/A-18F Super Hornet aircraft, that are capable of jamming radar and other advanced capabilities. Growlers are operated buy the U.S. and Australia. The United Arab Emirates, one of Washington's closest Middle East allies, has long expressed interest in acquiring the stealthy F-35 jets and was promised a chance to buy them in a side deal made when they agreed to normalize relations with Israel. The informal notification for 50 Lockheed Martin Co F-35 jets was made on Oct. 29. But any deal the U.S. makes to sell weapons in the region must satisfy decades of agreement with Israel where the U.S.-made weapon must not impair Israel's “qualitative military edge,” guaranteeing U.S. weapons furnished to Israel are “superior in capability” to those sold to its neighbors. https://www.reuters.com/article/us-usa-emirates-drones-exclusive/exclusive-trump-administration-advances-2-9-billion-drone-sale-to-uae-sources-idUSKBN27M06L

All news